Today's Low
₹ 152.00
Today's High
₹ 159.60
52 Weeks Low
₹ 33.30
52 Weeks High
₹ 74.30
Lower
₹ 150.75
Upper
₹ 166.55
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 171.2 | 97.5 | 93.6 | 98.2 | 77.7 | 191.7 | 163.9 | 181.1 | 186.7 | 190.0 | 224.8 |
Total Non-Current Assets | 173.7 | 182.3 | 181.7 | 184.5 | 191.7 | 216.8 | 223.9 | 214.7 | 219.4 | 583.0 | 583.9 |
Total Assets | 346.9 | 283.5 | 275.3 | 282.7 | 269.4 | 408.6 | 387.9 | 395.8 | 406.1 | 772.9 | 808.7 |
Total Current Liabilities | 359.8 | 355.4 | 311.0 | 361.6 | 348.3 | 401.9 | 298.6 | 264.9 | 259.4 | 447.4 | 465.8 |
Total Non-Current Liabilities | 10.6 | 84.4 | 107.7 | 130.4 | 105.8 | 159.9 | 251.4 | 298.2 | 311.7 | 346.8 | 271.7 |
Shareholder's Funds | -23.4 | -156.2 | -143.5 | -209.3 | -184.7 | -153.3 | -188.8 | -193.9 | -191.7 | -48.0 | 44.5 |
Total Liabilities | 346.9 | 283.5 | 275.3 | 282.7 | 269.4 | 408.6 | 387.9 | 395.8 | 406.1 | 772.9 | 808.7 |
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of -1.14, which results in a Positive aspect.
The Industry Price to BV stands at 6.03, vs the Price to BV of -40.77, which results in a Negative aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 0.30, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.26, which results in a Negative aspect.
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 511.2 | 392.5 | 367.5 | 391.4 | 371.1 | 433.8 | 423.3 | 249.9 | 661.9 | 459.1 | 386.3 |
Total Expenditure | 479.5 | 376.9 | 389.1 | 378.0 | 439.0 | 415.3 | 390.9 | 228.5 | 637.7 | 491.2 | 389.1 |
Operating Profit(Excl OI) | 36.8 | 20.4 | 24.6 | 24.9 | 8.8 | 108.2 | 33.8 | 27.9 | 35.5 | -27.3 | 10.5 |
Add: Other Income | 5.1 | 4.8 | 46.2 | 11.5 | 76.7 | 89.7 | 1.4 | 6.5 | 11.3 | 4.8 | 13.3 |
Operating Profit | 36.8 | 20.4 | 24.6 | 24.9 | 8.8 | 108.2 | 33.8 | 27.9 | 35.5 | -27.3 | 10.5 |
Less: Interest | 20.6 | 23.1 | 32.9 | 39.9 | 30.9 | 35.5 | 31.9 | 18.6 | 48.3 | 37.2 | 40.2 |
PBDT | 16.2 | -2.7 | -8.3 | -15.0 | -22.1 | 72.7 | 1.9 | 9.3 | -12.8 | -64.5 | -29.7 |
Less: Depreciation Amortization | 11.5 | 9.8 | 9.7 | 10.0 | 10.3 | 10.3 | 9.1 | 4.8 | 23.4 | 22.6 | 17.0 |
PBT & Exceptional Items | 4.8 | -12.4 | -18.0 | -25.0 | -32.4 | 62.4 | -7.2 | 4.5 | -36.2 | -87.1 | -46.7 |
Less: Exceptional Income Expenses | 76.4 | 0.0 | 82.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -88.7 | 0.0 | 7.8 |
Profit Before Tax | 81.1 | -12.4 | 64.7 | -25.0 | -32.4 | 62.4 | -7.2 | 4.5 | -124.9 | -87.1 | -38.9 |
Less: Taxation | -0.4 | 0.2 | 0.2 | -0.1 | -0.4 | 0.4 | 0.0 | 1.3 | 2.9 | 0.1 | 0.0 |
Profit After Tax | 81.5 | -12.6 | 64.5 | -24.9 | -32.0 | 62.0 | -7.2 | 3.2 | -127.7 | -87.2 | -38.9 |
Earnings Per Share | 0.3 | -0.1 | 0.3 | -0.1 | -0.1 | 0.3 | 0.0 | 0.0 | -0.6 | -0.5 | -0.2 |
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Growth stands at 32.18, vs the PAT Growth of 359.43, which results in a Positive aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 21.31, which results in a Negative aspect.
The Industry PAT Margin stands at 9.77, vs the PAT Margin of 17.38, which results in a Positive aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -10.3 | 81.1 | -12.4 | 64.7 | -25.0 | -32.4 | 62.4 | -7.1 | 4.5 | -124.9 | -87.1 | -38.9 |
Tax Paid | -0.2 | -0.2 | -1.1 | 0.0 | -0.1 | -0.9 | 0.0 | 0.0 | -0.1 | -0.2 | 0.0 | -0.2 |
Adjustment | 37.0 | -43.7 | 33.2 | -41.4 | 42.9 | 39.7 | -37.3 | 47.8 | 22.6 | 191.2 | 93.6 | 60.0 |
Changes In Working Capital | -10.3 | 81.1 | -12.4 | 64.7 | -25.0 | -32.4 | 62.4 | -7.1 | 4.5 | -124.9 | -87.1 | -38.9 |
Cash Flow after changes in Working Capital | 20.0 | 40.7 | 17.8 | 44.2 | 29.8 | 33.4 | 43.4 | 43.1 | 40.2 | 68.4 | 87.5 | 9.3 |
Cash Flow from Operating Activities | 19.8 | 40.5 | 16.7 | 44.1 | 29.7 | 32.5 | 43.4 | 43.1 | 40.2 | 68.2 | 87.4 | 9.1 |
Cash Flow from Investing Activities | -8.8 | 0.6 | 8.0 | 63.7 | -3.1 | -1.4 | -13.1 | -19.6 | -5.3 | -6.2 | -20.5 | -31.5 |
Cash Flow from Financing Activities | -32.0 | -28.6 | -17.4 | -107.9 | -26.8 | -33.3 | -26.9 | -28.1 | -29.5 | -70.7 | -64.2 | 24.4 |
Net Cash Inflow / Outflow | -21.0 | 12.5 | 7.3 | -0.1 | -0.1 | -2.2 | 3.4 | -4.7 | 5.3 | -8.7 | 2.7 | 2.0 |
Opening Cash & Cash Equivalents | 22.5 | 10.0 | 2.7 | 2.7 | 2.9 | 5.0 | 1.6 | 6.3 | 1.0 | 9.7 | 6.9 | 5.0 |
Closing Cash & Cash Equivalent | 1.5 | 22.5 | 10.0 | 2.7 | 2.7 | 2.9 | 5.0 | 1.6 | 6.3 | 1.0 | 9.7 | 6.9 |
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of 1.03, which results in a Negative aspect.
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of 0.52, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 1,455.0 | 1,444.6 | 1,462.9 | 1,329.8 | 1,257.8 | 1,239.6 | 1,169.4 | 1,343.9 | 1,248.4 | 1,240.9 | 1,278.6 | 1,204.5 | 1,097.0 | 952.1 | 671.6 | 670.7 |
Total Income | 1,461.9 | 1,452.2 | 1,469.0 | 1,309.1 | 1,260.4 | 1,247.4 | 1,188.8 | 1,350.4 | 1,250.9 | 1,244.0 | 1,281.7 | 1,216.6 | 1,105.0 | 953.4 | 674.3 | 677.5 |
Total Expenditure | 1,243.5 | 1,271.2 | 1,329.4 | 1,188.1 | 1,193.2 | 1,183.6 | 1,199.8 | 1,215.8 | 1,160.0 | 1,169.8 | 1,213.1 | 1,222.2 | 959.4 | 862.3 | 701.2 | 749.4 |
PBIDT (Excl OI) | 211.5 | 173.4 | 133.5 | 141.6 | 64.6 | 56.0 | -30.4 | 128.1 | 88.4 | 71.1 | 65.5 | -17.7 | 137.6 | 89.8 | -29.6 | -78.7 |
Other Income | 6.9 | 7.6 | 6.2 | -20.6 | 2.6 | 7.8 | 19.4 | 6.4 | 2.6 | 3.1 | 3.1 | 12.1 | 8.0 | 1.3 | 2.6 | 6.8 |
Operating Profit | 218.4 | 181.0 | 139.7 | 121.0 | 67.2 | 63.8 | -11.1 | 134.6 | 91.0 | 74.2 | 68.5 | -5.6 | 145.6 | 91.1 | -26.9 | -71.9 |
Interest | 82.6 | 76.7 | 57.9 | 75.2 | 66.3 | 39.4 | 33.1 | 47.9 | 56.4 | 51.6 | 50.2 | 57.9 | 62.1 | 50.2 | 60.5 | 104.1 |
Exceptional Items | 0.0 | 0.0 | 0.0 | -5.9 | 0.0 | 0.0 | 0.0 | 763.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 826.4 |
PBDT | 135.8 | 104.3 | 81.8 | 39.9 | 0.8 | 24.4 | -44.2 | 850.3 | 34.6 | 22.5 | 18.3 | -63.4 | 83.5 | 40.9 | -87.5 | 650.4 |
Depreciation | 33.2 | 32.4 | 31.9 | 30.7 | 31.3 | 31.5 | 30.3 | 30.0 | 30.3 | 27.8 | 26.4 | 25.9 | 23.9 | 24.0 | 23.7 | 23.7 |
Profit Before Tax | 102.6 | 71.9 | 49.9 | 9.2 | -30.5 | -7.1 | -74.5 | 820.3 | 4.3 | -5.3 | -8.1 | -89.3 | 59.6 | 16.8 | -111.2 | 626.7 |
Tax | -0.2 | -1.8 | 3.0 | -1.0 | 2.3 | 1.8 | -2.1 | -5.1 | 0.6 | 0.6 | 0.6 | 0.3 | 0.5 | 0.8 | 0.4 | 2.9 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 102.7 | 73.6 | 46.9 | 10.2 | -32.8 | -8.9 | -72.5 | 825.5 | 3.7 | -5.8 | -8.6 | -89.6 | 59.1 | 16.0 | -111.6 | 623.8 |
Net Profit | 102.7 | 73.6 | 46.9 | 10.2 | -32.8 | -8.9 | -72.5 | 825.5 | 3.7 | -5.8 | -8.6 | -89.6 | 59.1 | 16.0 | -111.6 | 623.8 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 327.5 | 327.4 | 327.1 | 327.1 | 327.1 | 327.0 | 327.0 | 326.7 | 326.7 | 326.6 | 326.6 | 250.2 | 250.2 | 250.2 | 250.0 | 250.0 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 3.1 | 2.3 | 1.4 | 0.3 | -1.0 | -0.3 | -2.2 | 25.6 | 0.1 | -0.2 | -0.3 | -3.6 | 2.4 | 0.7 | -4.5 | -8.5 |
Operating Profit Margin | 15.0 | 12.5 | 9.5 | 9.1 | 5.3 | 5.1 | -0.9 | 10.0 | 7.3 | 6.0 | 5.4 | -0.5 | 13.3 | 9.6 | -4.0 | -10.7 |
Net Profit Margin | 7.1 | 5.1 | 3.2 | 0.8 | -2.6 | -0.7 | -6.2 | 61.4 | 0.3 | -0.5 | -0.7 | -7.4 | 5.4 | 1.7 | -16.6 | 93.0 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of -6.11, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -12.23, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 176.30 | 186.79 | 158.68 |
R3 | 169.12 | 170.23 | 155.34 |
R2 | 161.93 | 162.49 | 154.23 |
R1 | 156.97 | 158.08 | 153.11 |
Pivot | 149.78 | 150.34 | 149.78 |
S1 | 144.82 | 145.93 | 150.89 |
S2 | 137.63 | 138.19 | 149.77 |
S3 | 132.67 | 133.78 | 148.66 |
S4 | 127.70 | 113.89 | 145.32 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
63.05
Neutral
RSI
54.29
Neutral
ROC
-0.22
Bearish
UltimateOscillator
58.26
Neutral
Williams Indicator
-46.04
Neutral
CCI Indicator
46.71
Neutral
MACD
-2,812.30
Bearish
Stochastic Indicator
36.45
Neutral
ATR
8.56
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
24-01-2024 | Quarterly Results |
20-10-2023 | Inter-alia, to consider and evaluate proposals for raising of funds by way of a preferential issue/allotment and private placement to promoters/promoter group of the Company, by way of issue f equity shares or warrants or other securities convertible into equity shares, which may or may not be listed. |
11-08-2023 | Quarterly Results |
26-06-2023 | Audited Results (Revised) |
09-06-2023 | Audited Results |
30-05-2023 | Audited Results |
30-05-2023 | Audited Results(Cancelled) (Cancelled) |
14-02-2023 | Quarterly Results |
28-11-2022 | Quarterly Results (Revised) |
11-11-2022 | Quarterly Results |
10-08-2022 | Quarterly Results |
22-06-2022 | Audited Results |
17-02-2022 | Preferential Issue of shares Inter-alia, to consider and evaluate any and all proposals for raising of funds by way of a preferential issue/ allotment, private placement including a qualified institutions placement or foreign currency convertible bonds or tlu?ough any other permissible mode and/ or combination thereof, as may be considered appropriate, by way of issue of equity shares or warrants or other securities convertible into equity shares or bonds including foreign currency convertible bonds, convertible debentures and/or non-convertible debentures including non-convertible debentures along with warrants, which may or may not be listed. The Board, if required, would also consider conducting an extraordinary general meeting/ postal ballot process to seek approval of the shareholders in respect of the aforesaid proposal. |
08-02-2022 | Quarterly Results |
25-11-2021 | Quarterly Results (Revised) |
12-11-2021 | Quarterly Results |
20-10-2021 | Quarterly Results |
20-09-2021 | WANBURY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2021 ,inter alia, to consider and approve This is with reference to our earlier letter dated 3rd August, 2021 and 9th August, 2021 regarding the meeting of Board of Directors of Wanbury Limited which is scheduled to be held on 20th September, 2021 inter-alia to consider and approve the Un-Audited Financial Results for the first quarter and three months ended 30th June, 2021. In this regard, we hereby inform you that the meeting is further deferred/ postponed due to the circumstances beyond our control and other administrative reasons and the Meeting of the Board of Directors is now re-scheduled to be held on Wednesday, 20th October, 2021. Further, as per SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in Securities of the Company shall now remain closed for the Companys Directors/Officers/Key Managerial Personnel/ Designated Employees of the Company w.e.f. 1st July, 2021 till the close of business hours on 22nd October, 2021 (both days inclusive). |
20-09-2021 | Quarterly Results (Revised) |
12-08-2021 | Audited Results |
28-06-2021 | Quarterly Results & Audited Results |